'Pharma Bro' Shkreli Aims Another Blow At Kidney Drug Suit

By Nadia Dreid (April 2, 2020, 4:31 PM EDT) -- Incarcerated "pharma bro" Martin Shkreli and his former company Retrophin Inc. are trying once again to convince a Pennsylvania federal judge to let them out of a suit alleging they tried to keep a generic competitor to their kidney drug Thiola out of the market.

Retrophin accused Spring Pharmaceuticals of "being nothing more than a legal vehicle created to pursue this litigation" in the Wednesday filing seeking to escape the antitrust claims.

In a separate motion to dismiss, former owner Shkreli co-signed that filing, asking the suit to be booted for "the reasons articulated by Retrophin."

"Spring, claiming to be a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!